Disease | Gender (M/F) | Age (years) (range, mean) | Interventions | Course | Clinical efficiency | Reported indicators in QBD group | References |
---|---|---|---|---|---|---|---|
Sepsis | E: 11/7 C: 12/8 | E: 53.27 ± 9.24 C: 51.00 ± 11.29 | E: Conventional therapy + QBD (100 ml/time, tid.) C: Conventional therapy | 7 days | E: 83.33% C:75.00% | IgG↓, IgA↓, IgM↓, C3↓, CRP↑, TNF-α↓, APACHEII score↓, TCM symptom score↓ | Zhang et al. [51] |
Sepsis | E: 18 C: 20 | NR | E: Conventional therapy + QBD (100 ml/time, tid.) C: Conventional therapy | 7 days | E: 83.33% C: 75.00% | TCM symptom score↓, APACHEII score↓, IgG↓, IgA↓, IgM↓, C3↓, CRP↑, TNF-α↓ | Leng et al. [18] |
Sepsis | E: 11/7 C: 12/8 | E: 53.27 ± 9.24 C: 51.00 ± 11.29 | E: Conventional therapy + QBD (200 ml/time, tid.) C: Conventional therapy | 7 days | E: 83.30% C: 75.00% | TCM symptom score↓, APACHEII score↓, mortality rate↓, PT↓, APTT↓, TT↓, PLT↑ | Fu et al. [54] |
Sepsis | E: 15/10 C: 16/8 | E: 53.27 ± 9.20 C: 51.00 ± 11.29 | E: Conventional therapy + QBD (100 ml/time, tid.) C: Conventional therapy | 7 days | E: 84.00% C: 75.00% | TCM symptom score↓, APACHEII score↓, IgG↓, IgA↓, IgM↓, C3↓, CRP↑, TNF-α↓ | Leng et al. [52] |
Sepsis | E: 19/23 C: 22/20 | E: 50–74, 61 ± 8.6 C: 52–75, 63 ± 7.3 | E: Antibiotic therapy + QBD (100 ml/time, bid.) C: Antibiotic therapy | 7 days | E: 80.95% C: 64.28% | APACHEII score↓, IgG, ↓ IgA↓, IgM↓, C3↓, CRP↑, TNF-α↓ | Chen [17] |
AKI with sepsis | E: 28/29 C: 30/26 | E: 68.10 ± 9.07 C: 69.49 ± 8.37 | E: Conventional therapy + QBD (200 ml/day, bid.) C: Conventional therapy | 7 days | NR | APACHEII score↓, Scr↓, BUN↓, CRP↓, TNF-α↓, IL-1β↓, IL-6↓, IL-10↓ | Ge et al. 2014 [37] |
Pathogen-invading-lung syndrome with sepsis | E: 15/9 C: 13/11 | E: 68.10 ± 9.07 C: 69.49 ± 8.37 | E: Conventional therapy + QBD (100 ml/time, bid.) C: Conventional therapy | 7 days | E: 95.83% C: 83.33% | APACHEII score↓, CRP↓, WBC↓, TCM symptom score↓, blood glucose↑, antipyretic time↓ | Xi et al. [20] |
Sepsis with heat poisoning syndrome | E: 35/24 C: 37/21 | E: 46–68, 50.4 ± 8.5 C: 44–70, 51.8 ± 7.9 | E: Conventional therapy + Xuebijing injection (100 mg/time, bid.) + QBD (200 mg/time, bid.) C: Conventional therapy | 7 days | E: 77.97% C: 42.37% | APACHEII↓, SOFA score↓, TNF-α↓, IL-1β↓, IL-6↓, IL-10↑, d-lactic acid↓, endotoxin↓, PCT↓, whole blood viscosity↓, plasma viscosity↓, erythrocyte deformation index↓, erythrocyte aggregation index↓, PT↑, APTT↓, TT↑, FIB↓, D–D↓, PLT↓ | Ren et al. [14] |
Coagulation dysfunction in sepsis | E: 20/13 C: 19/12 | E: 28–78, 60.94 ± 12.13 C: 28–79, 61.45 ± 12.91 | E: Conventional therapy + QBD (100 ml/day, bid.) C: Conventional therapy | 7 days | E: 93.90% C: 74.20% | PLT↑, PT↓, APTT↓, Fib↓, D–D↓, TCM symptom score↓, APACHEII score↓, SOFA score↓ | Gao et al. [19] |
Influenza A (H1N1) with respiratory distress syndrome | 2/11 | 12–61, 29.4 ± 14.1 | Conventional therapy + QBD | 7–48 days | 92.31% | 11 cases were cured, 1 case was effective and 1 case was ineffective | Chu et al. [40] |
Viral pneumonia caused by influenza A virus subtype H1N1 | E: 28/22 C: 24/16 | E: 40.67 ± 2.09 C: 41.68 ± 4.68 | E: Conventional therapy + QBD (200 ml/day, tid.) + Tanreqing injection (30 ml/day, qd.) C: Conventional therapy | 7 days | E: 96.00% C: 70.00% | TNF-α↓, IL-6↓, IL-8↓, IL-10↑, CRP↓, TCM symptom score↓ | Tian et al. [15] |
SARS | 4/6 | 15–70, 43.77 ± 12.68 | Conventional therapy + QBD (150 ml/time, bid.) | 5 days | NR | Antipyretic time↓, temperature gradually drops to normal level | Zhang et al. [45] |
EV 71 | E: 22/8 C: 21/9 | E: 2.0 ± 1.3 C: 2.1 ± 0.25 | E: Conventional therapy + QBD (50 ml/time, bid. ~ tid.) C: Conventional therapy | 3–5 days | E: 93.33% C: 63.40% | Antipyretic time↓, hospital stay↓ | Zhan et al. [43] |
Epidemic encephalitis type B | 10/6 | 1–11, 5.3 | QBD (tid.) | NR | 87.50% | 10 cases were cured, 4 cases were improved and 2 cases were ineffective. | Yang [33] |
Pneumonia | E: 30 C: 30 (36/24) | E: 20–70, 53.11 ± 10.58 C: 18–67, 49.00 ± 10.61 | E: Levofloxacin + QBD (150 ml/time, bid.) C: Levofloxacin (0.5 g, qd.) | 7 days | E: 96.67% C: 86.67% | Antipyretic time↓, WBC↓, NG↓ | Nie et al. [66] |
Mycoplasma pneumonia | E: 20/25 C: 22/23 | E: 9–58, 27 C: 10–63, 25 | E: Azithromycin (10 mg/kg/day, i.v.) + QBD + Canopy bulk C: Azithromycin (10 mg/kg/day, i.v.) | 4 W | E: 100.00% C: 86.67% | Blood routine was normal, clinical symptoms disappeared, chest X-ray improved | Shu [67] |
Infant pneumonia | E: 22/20 C: 23/20 | E: 0.58–9 C: 0.58–8 | E: Conventional therapy + QBD (3–5 ml/kg, bid.) C: Conventional therapy | 5 days | E: 97.62% C: 81.40% | NR | Yao et al. [30] |
Epidemic hemorrhagic fever | E: 84/36 C: 40/20 | E: 10–17 (13 cases); 18–49 (82 cases), 50–70 (25 cases) C: 10–17 (4 cases); 18–49 (47 cases), 50–70 (9 cases) | E: Ribavirin (15 mg/kg, qd.) + QBD (bid.) C: Ribavirin (15 mg/kg, qd.) | NR | NR | Days of fever↓, polyuria↓, platelet recovery↓, urine protein turning negative↓, the rate of oliguria and hypotension shock↑, adverse reactions ↓ | Hao et al. [27] |
Hyperthermia | E: 14/12 C: 11/15 | E: 18–62 C: 19–63 | E: QBD (150 ml/time, bid.) C: Angong Niuhuang Pill (1 pill, qd ~ bid.) | NR | E: 92.30% C: 57.69% | NR | Wang et al. [55] |
Hemorrhagic fever with renal syndrome | E: 45 C: 45 (51/39) | 24–48 | E: Conventional therapy + QBD (bid.) C: Conventional therapy | 7 days | NR | CD4+↑, CD8+↓, CD4+/CD8+↑ | Li et al. [26] |
Infectious mononucleosis | E: 46 C: 45 (43/48) | 0.83–6 | E: Ganciclovir (10 mg/kg d, bid.) + QBD (bid. ~ tid.) C: Ganciclovir (10 mg/kg d, bid.) | 7 days | E: 93.48% C: 80.00% | NR | Dong [41] |
Infectious mononucleosis in children | E: 11/9 C: 12/8 | E: 2–13 C: 3–12 | E: ganciclovir (5 mg/kg) + QBD (200 ml/time, qid.) C: ganciclovir (5 mg/kg) | 7–14 days | E: 95.00% C: 80.00% | Duration of main clinical manifestations↓, WBC↓, heterotypic lymphocyte↓, liver function indices↓ | Sheng et al. [42] |
Epidemic cerebrospinal meningitis | 40/22 | 8–40, 18 | QBD (tid.) | 15 days | 98.39% | NR | Sun et al. [29] |
Hand-foot-and-mouth disease | E: 30/20 C: 25/25 | E: 1–3 (37 cases), 4–5 (13 cases) C: 1–3 (36 cases), 4–5 (14 cases) | E: Ribavirin (10–15 ml/kg, qd.) + QBD (100–150 ml/day, tid. ~ qid.) C: Ribavirin (10–15 ml/kg, qd.) | 10 days | E: 94.00% C: 88.00% | Antipyretic time↓, disappearance time of oral herpes↓, severe conversion rate↓ | Xu et al. [68] |
Erythroderma psoriasis | E: 14/15 C: 16/13 | E: 20–63, 46.35 ± 2.16 C: 20–64, 47.32 ± 2.61 | E: QBD (200 ml/time, tid.) C: Acitretin capsules (20 mg/kg) | 3 M | E: 96.55% C: 75.86% | Adverse reactions ↓ | Li [69] |